Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

ON THIS PAGEBrain MetastasisSigns and SymptomsDiagnosisTreatmentPrognosis and OutlookLung cancer is one of the kinds of cancer that is most likely to spread to the brain. Approximately 20 percent of ...

The U.S. Food and Drug Administration had approved Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The efficacy of the ...

This can disrupt the cancer cell’s life cycle and may lead to cell death. The FDA granted accelerated approval to Zepzelca in June 2020 for those whose metastatic small cell lung cancer has progressed ...

News Business Wire U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer ...

The FDA has approved AbbVie’s telisotuzumab vedotin (Emrelis) for locally advanced or metastatic, non-squamous non-small-cell lung cancer (NSCLC) with high c-MET protein overexpression after ...

The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths ...

Phase III trials of BNT327 are ongoing in extensive-stage small-cell lung cancer and in NSCLC. A phase III trial in triple-negative breast cancer is set to start later this year.